Breast cancer patients with HER2-low and HER2–0 did not differ significantly in terms of near-term efficacy (pCR rate) and long-term prognosis (DFS and OS) after neoadjuvant chemotherapy, although patients showing HER2-low in the HR-subgroup of patients may have worse DFS. This evidence concerns the gene ERBB2 and breast carcinoma.